EYES has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EYES has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Second Sight Medical Products's enterprise value is $-1.84 Mil. Second Sight Medical Products's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-9.08 Mil. Therefore, Second Sight Medical Products's EV-to-EBITDA for today is 0.20.
The historical rank and industry rank for Second Sight Medical Products's EV-to-EBITDA or its related term are showing as below:
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-11), Second Sight Medical Products's stock price is $4.14. Second Sight Medical Products's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.660. Therefore, Second Sight Medical Products's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Second Sight Medical Products's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Second Sight Medical Products Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -3.63 | -1.85 | -2.79 | -3.39 | 0.58 |
Second Sight Medical Products Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -15.26 | -6.10 | 0.58 | 0.37 | -2.62 |
For the Medical Devices subindustry, Second Sight Medical Products's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Second Sight Medical Products's EV-to-EBITDA falls into.
Second Sight Medical Products's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -1.841 | / | -9.077 | |
= | 0.20 |
Second Sight Medical Products's current Enterprise Value is $-1.84 Mil.
Second Sight Medical Products's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Second Sight Medical Products (NAS:EYES) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Second Sight Medical Products's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 4.14 | / | -0.660 | |
= | At Loss |
Second Sight Medical Products's share price for today is $4.14.
Second Sight Medical Products's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Second Sight Medical Products's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Lisa Ellen Porter | officer: Chief Medical Officer | 778 CORDILLERAS AVE, SAN CARLOS CA 94070 |
Donald Dwyer | officer: Chief Business Officer | 54 CHERRY FARM LANE, WEST CHESTER PA 19382 |
Truc Le | officer: COO | 1905 WEST RED FOX ROAD, SANTA ANA CA 92704 |
Adam Mendelsohn | director, officer: CEO | C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608 |
Brigid Makes | officer: CFO | 20245 SW 95TH AVENUE, TUALATIN OR 97062 |
Gregg Williams | director, 10 percent owner | PO BOX 200, WALLED LAKE MI 48390-0200 |
Wilford Dean Baker | director | 200 FLYNN ROAD, CAMARILLO CA 93012-8790 |
Larson Alexandra L.p. | director | 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302 |
Scott Dunbar | officer: Acting CEO | 13170 TELFAIR AVENUE, SYLMAR CA 91342 |
Edward Jonathon Sedo | officer: Controller | 4485 FORESTGLEN CT, MOORPARK CA 93021 |
Jonathan Will Mcguire | director, officer: Chief Executive Officer | 96 TALAMINE COURT, COLORADO SPRINGS CO 80907 |
Jessy Dana Dorn | officer: VP-Clin & Scientific Affairs | 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342 |
Edward David Randolph | officer: Vice President Manufacturing | 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342 |
Matthew J Pfeffer | director | |
Aaron Mendelsohn | director | 224 15TH STREET, SANTA MONICA CA 90402 |
From GuruFocus
By Business Wire Business Wire • 02-09-2022
By Business Wire Business Wire • 09-22-2020
By Business Wire Business Wire • 08-31-2022
By PRNewswire PRNewswire • 02-17-2022
By Business Wire Business Wire • 06-22-2021
By Business Wire Business Wire • 04-28-2020
By Business Wire Business Wire • 07-18-2022
By Business Wire Business Wire • 06-23-2021
By Business Wire Business Wire • 08-11-2021
By Business Wire Business Wire • 03-05-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.